Immunotherapy for adenosquamous carcinoma in the elderly: A case report and literature review
10.3760/cma.j.issn.0254-9026.2020.06.019
- VernacularTitle:高龄肺腺鳞癌患者免疫治疗一例并文献复习
- Author:
Min LI
1
;
Wei XU
;
Yan CHEN
;
Shuangshuang WU
;
Jianqing WU
Author Information
1. 南京医科大学第一附属医院老年医学科 老年医学重点实验室，南京 210029
- From:
Chinese Journal of Geriatrics
2020;39(6):689-692
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the application of immunotherapy and whole course management of immune-related adverse reactions in elderly patients with lung adenosquamous carcinoma.Methods:Clinical data of an 83-year-old patient with advanced lung adenosquamous carcinoma who underwent immunotherapy during hospitalization were retrospectively analyzed.Clinical features of immunotherapy for elderly patients with lung cancer were analyzed.Results:Compared with younger patients, immunotherapy for adenocarcinoma has similar clinical benefits and toxicity in the elderly.However, immunosenescence and comorbidity in the elderly and immune-related complications such as the progression of interstitial pneumonia, are common in the elderly.Conclusions:There is no evident age-related difference in the benefit of immunotherapy.For patients of advanced age with multiple complications and frailty, a comprehensive geriatric assessment may help improve clinical prognosis.
